Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody

British Journal of Dermatology

Volumn 162, Issue 2, 2010, Pages 337-344

  Marie, I ^a   Lahaxe, L ^a   Benveniste, O ^b   Delavigne, K ^c   Adoue, D ^c   Mouthon, L ^d   Hachulla, E ^e   Constans, J ^f   Tiev, K ^g   Diot, E ^h   Levesque, H ^a   Boyer, O ^a   Jouen, F ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CHU RANGUEIL   (France)

^d CHU Cochin ^*  (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Anti PM Scl antibody; Dermatomyositis; Interstitial lung disease; Polymyositis; Prognosis

Indexed keywords

ANTIBODY; AZATHIOPRINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PM SCL ANTIBODY; STEROID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTISYNTHETASE SYNDROME; ARTHRALGIA; ARTHRITIS; ARTICLE; ASPIRATION PNEUMONIA; CLINICAL ARTICLE; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE COURSE; ESOPHAGUS DISEASE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTERSTITIAL LUNG DISEASE; MALE; MEDICAL RECORD REVIEW; MORTALITY; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; BIOLOGICAL MARKERS; DERMATOMYOSITIS; DRUG THERAPY, COMBINATION; EXORIBONUCLEASES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; STEROIDS; TIME FACTORS; YOUNG ADULT;

EID: 74349090383     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09484.x     Document Type: Article

References (59)

1. Callen JP. Dermatomyositis. Lancet 2000 355 : 53 7.
2. Danko K, Ponyi A, Constantin T et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004 83 : 35 42.
3. Marie I, Hachulla E, Chérin P et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002 47 : 614 622.
4. Marie I, Hachulla E, Hatron PY et al. Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors. J Rheumatol 2001 28 : 2230 2237.
5. Marie I, Hachulla E, Chérin P et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005 53 : 155 165.
6. Marie I, Hatron PY, Levesque H et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999 78 : 139 147.
7. Troyanov Y, Targoff IN, Tremblay JL et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005 84 : 231 249.
8. Wolfe JF, Adelstein E, Sharp GC. Antinuclear antibody with distinct specificity for polymyositis. J Clin Invest 1977 59 : 176 178.
9. Raijmakers R, Renz M, Wiemann C et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. Arthritis Rheum 2004 50 : 565 569.
10. Brouwer R, Vree Egberts WTM, Hengstman GJD et al. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 2002 4 : 134 138.
11. Brouwer R, Hengstman GJD, Vree Egberts WTM et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001 60 : 116 123.
12. Blaszczyk M, Jarzabek-Chorelska M, Jablonska S et al. Autoantibodies to nucleolar antigens in systemic sclerosis: clinical correlations. Br J Dermatol 1990 123 : 421 430.
13. Duncan AG, Richardson JB, Klein JB et al. Clinical, serologic, and immunogenetic studies in patients with dermatomyositis. Acta Derm Venereol (Stockh) 1991 71 : 312 316.
14. Garcia-Patis V, Bartralot R, Fonosella V et al. Childhood sclerodermatomyositis: report of a case with the anti-PM-Scl antibody and mechanic's hands. Br J Dermatol 1996 135 : 613 616.
15. Genth E, Mierau R, Genetzky P et al. Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum 1990 33 : 657 665.
16. Ghirardello A, Zampieri S, Tarricone E et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity 2006 39 : 217 221.
17. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997 40 : 1257 1266.
18. Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007 6 : 432 437.
19. Mahler M, Raijmakers R, Dähnrich C et al. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther 2005 7 : R704 13.
20. Meyer O, Cremer-Legmann F, Haim T, Ryckewaert A. Principaux anticorps antinucléaires et anticytoplasmiques au cours des polymyosites et des dermatomyosites. Etude de 42 observations. Presse Med 1987 16 : 155 158.
21. Oddis CV, Okano Y, Rudert WA et al. Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum 1992 35 : 1211 1217.
22. Reichlin M, Arnett FC. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984 27 : 1150 1156.
23. Reichlin M, Maddison P, Targoff IN et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 1984 4 : 40 4.
24. Reimer G, Steen VD, Penning CA et al. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1988 31 : 525 532.
25. Schnitz W, Taylor-Albert E, Targoff IN et al. Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma. J Rheumatol 1996 23 : 1729 1733.
26. Török L, Danko K, Cserni G, Szûcs G. PM-Scl autoantibody positive scleroderma with polymyositis (mechanic's hand: clinical aid in the diagnosis). J Eur Acad Dermatol Venereol 2004 18 : 356 359.
27. Treadwell EL, Alspaugh MA, Wolfe JF, Sharp GC. Clinical relevance of PM-1 antibody and physiochemical characterization of PM-1 antigen. J Rheumatol 1984 11 : 658 662.
28. Vandergheynst F, Ocmant A, Sordet C et al. Anti-PM/Scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients. Clin Exp Rheumatol 2006 24 : 129 133.
29. Warner NZ, Greidinger EL. Patients with antibodies to both PmScl and dsDNA. J Rheumatol 2004 31 : 2169 2174.
30. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975 292 : 344 347.
31. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975 292 : 403 407.
32. Marie I, Hachulla E, Levesque H et al. Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis. J Rheumatol 1999 26 : 2706 2709.
33. Schwarz MI. The lung in polymyositis. Clin Chest Med 1998 19 : 701 712.
34. Selva-O'Callaghan A, Labrador-Horrillo M, Solans-Laque R et al. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 2006 55 : 791 798.
35. Benbassat J, Gefel D, Larholt K et al. Prognostic factors in polymyositis/dermatomyositis. Arthritis Rheum 1985 28 : 249 255.
36. Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977 56 : 255 286.
37. De Vere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain 1975 98 : 637 666.
38. Henriksson KG, Sandstedt P. Polymyositis - treatment and prognosis: a study of 107 patients. Acta Neurol Scand 1982 65 : 280 300.
39. Henriksson KG, Lindvall B. Polymyositis and dermatomyositis 1990 - diagnosis, treatment and prognosis. Prog Neurobiol 1990 35 : 181 193.
40. Koh ET, Seow A, Ong B et al. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 1993 52 : 857 861.
41. Marie I, Hatron PY, Hachulla E et al. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998 25 : 1336 1343.
42. Medsger TA Jr., Robinson H, Masi AT. Factors affecting survivorship in polymyositis: a life-table study of 124 patients. Arthritis Rheum 1971 14 : 249 258.
43. Selva-O'Callaghan A, Mijares-Boechk-Behrens T, Labrador-Horrillos M et al. Anti-PM-Scl antibodies in a patient with inclusion body myositis. Rheumatology (Oxford) 2003 42 : 1016 1018.
44. Buchbinder R, Forbes A, Hall S et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001 134 : 1087 1095.
45. András C, Ponyi A, Constantin T et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008 35 : 438 444.
46. Chow WH, Gridley G, Mellemkjaer L et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995 6 : 9 13.
47. Chinoy H, Fertig N, Oddis CV et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007 66 : 1345 1349.
48. Fardet L, Dupuy A, Gain M et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009 88 : 91 7.
49. Hill CL, Zhang Y, Sigurgeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001 357 : 96 100.
50. Levine SM. Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 2006 18 : 620 624.
51. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003 362 : 971 982.
52. Love A, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991 70 : 360 374.
53. Goldstein R, Duvic M, Targoff IN et al. HLA-D region genes associated with autoantibody responses to histidyl-tranfer RNA synthetase (Jo-1) and other translation-related factors in myositis. Arthritis Rheum 1990 33 : 1240 1248.
54. Marguerie C, Bunn CC, Copier J et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992 71 : 327 336.
55. Douglas WW, Tazelaar HD, Hartman TE et al. Polymyositis-dermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med 2001 164 : 1182 1185.
56. Fathi M, Vikgren J, Boijsen M et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008 59 : 677 685.
57. Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2000 12 : 501 508.
58. Lakhanpal S, Lie JY, Conn DL, Martin WJ II. Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 1987 46 : 23 9.
59. Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis is correlated with histologic findings. Am Rev Respir Dis 1990 141 : 727 733.